Vendor Intelligence Report: Mokemei Zhengzhou Biotechnology MKM

Published 13 Jun 2026. 22-page investigative report on who is behind Mokemei Zhengzhou Biotechnology MKM: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 6 Finnrick lab tests, MKM is 6 pass / 0 fail for an overall pass rate of 100%. The result is narrow: every supplied Finnrick sample is Retatrutide, not the broader catalog. For MKM Retatrutide, the signal is directionally encouraging; for other peptides, this dossier supplies no independent Finnrick pass/fail basis.

The positive record still needs verification. The captured Retatrutide table shows sparse batch identification, with only one usable batch marker found, and the methodology discussion points to dose/fill precision as the stricter-grade pressure point. MKM therefore reads as acceptable with verification for Retatrutide, not as a premium traceability operation.

Beyond vial data, MKM is a real Zhengzhou entity, but registry snippets, WHOIS/Wayback records, and a located export record do not cleanly support the older-company story. The only trade record investigators found under the company name described construction aggregate, not peptides. The site also carries verification friction: an SSL warning, template social links, direct-inquiry pricing, and a same-server peptide-domain lead not yet tied by ownership records.

The reputation layer is sharper. GLP-1 Forum material shows a staff-heavy customer-review thread, a later-hidden vendor area, and a COA filename that attacks Finnrick instead of answering testing concerns with clean batch-matched counter-evidence. Reddit shipping complaints and a reported HYNH Telegram channel remain user-report/open-lead territory, but they materially affect channel verification, guarantee review, and reshipment terms before payment.

Inside the full report:

  • Per-product Retatrutide pass/fail record, captured test table and methodology-divergence charts.
  • Registry, WHOIS, Wayback and website-artifact timeline for MKM.
  • Trademo export capture and non-peptide cargo anomaly analysis.
  • GLP-1 Forum review-thread, hidden-subforum and anti-Finnrick COA-filename exhibits.
  • Same-server peptide-domain comparison and HYNH channel watch item.
  • Buyer-risk matrix for traceability, shipping, channel verification and reshipment terms.

Risk assessment

  • Corporate-history and provenance misrepresentation risk — high: Website claims 20+ years and a 2017 history, while located records show a Dec 22, 2021 entity, Apr 27, 2025 domain, and only a non-peptide gravel export record.
  • Review-manipulation and anti-testing conduct risk — high: Staff-dominated review thread, hidden/unavailable subforum, and a COA filename attacking Finnrick undermine independent buyer verification.
  • Retatrutide batch-traceability risk — medium: Retatrutide is 6 pass / 0 fail with an 85% rating, but the captured table recorded only one batch ID, PT40, limiting vial-to-result matching.
  • Untested non-Retatrutide catalog risk — medium: Finnrick coverage supplied for this dossier is Retatrutide only; no independent Finnrick pass/fail record is available here for other MKM catalog peptides.
  • Shipping and reshipment reliability risk — medium: Reddit reports describe Hong Kong delays, customs seizures, and a disputed 20% reshipment fee despite advertised clearance/reshipment assurances.
  • Brand/channel-confusion and possible evasive-rebrand risk — medium: HYNH/Freya Telegram outreach is reported but not fully mapped, and a-peptides.com shares MKM’s server IP without an explained authorization link.
  • Transaction-channel opacity risk — medium: Invalid SSL, placeholder social links, direct-inquiry pricing, and mixed US/UK/China contact presentation reduce authentication and payment-safety confidence.